A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome

Blood
Elaine Coustan-SmithDario Campana

Abstract

Bone marrow normal lymphoid progenitors (CD19+, CD10+, and/or CD34+) are exquisitely sensitive to corticosteroids and other antileukemic drugs. We hypothesized that, in patients with B-lineage acute lymphoblastic leukemia (ALL), cells with this phenotype detected early in treatment should be leukemic rather than normal. We therefore developed a simple and inexpensive flow cytometric assay for such cells and prospectively applied it to bone marrow samples collected on day 19 from 380 children with B-lineage ALL. In 211 patients (55.5%), these cells represented 0.01% or more of the mononuclear cells; results correlated remarkably well with those of more complex flow cytometric and molecular minimal residual disease (MRD) evaluations. Among 84 uniformly treated children, the 10-year incidence of relapse or remission failure was 28.8% +/- 7.1% (SE) for the 42 patients with 0.01% or more leukemic cells on day 19 detected by the simplified assay versus 4.8% +/- 3.3% for the 42 patients with lower levels (P = .003). These assay results were the strongest predictor of outcome, even after adjustment for competing clinicobiologic variables. Thus, this new assay would enable most treatment centers to identify a high proportion of children...Continue Reading

References

Dec 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D R MillerG D Hammond
Mar 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J E RubnitzF G Behm
Sep 14, 1999·Leukemia·J E RubnitzC H Pui
Mar 29, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Y ToyodaT Saito
Apr 6, 2000·The New England Journal of Medicine·M AricòG Masera
Sep 15, 2000·Journal of Immunological Methods·D Campana, F G Behm
Mar 22, 2002·The Lancet Oncology·T SzczepańskiJ J van Dongen
Aug 30, 2002·British Journal of Haematology·Tim Eden
Jun 6, 2003·British Journal of Haematology·Dario Campana
Jun 12, 2003·Current Opinion in Hematology·Lewis B Silverman, Stephen E Sallan
Apr 9, 2004·The New England Journal of Medicine·Ching-Hon PuiJames R Downing
May 27, 2004·JAMA : the Journal of the American Medical Association·Scott C HowardFrancisco Pedrosa
Jul 15, 2004·Blood·Ching-Hon PuiUNKNOWN Total Therapy Study XIIIB at St Jude Children's Research Hospital
May 27, 2005·The New England Journal of Medicine·Raul C Ribeiro, Ching-Hon Pui

❮ Previous
Next ❯

Citations

Jul 1, 2008·Current Hematologic Malignancy Reports·Dario Campana
May 15, 2010·Current Hematologic Malignancy Reports·Dario Campana
Mar 1, 2012·Current Hematologic Malignancy Reports·Dario Campana
May 4, 2012·Leukemia·J J M van DongenUNKNOWN EuroFlow Consortium (EU-FP6, LSHB-CT-2006-018708)
Jan 19, 2007·Nature Clinical Practice. Cardiovascular Medicine·Hüseyin Ince, Christoph A Nienaber
Apr 25, 2012·Current Opinion in Hematology·Dario Campana
Jan 18, 2011·Hematology·Dario Campana
May 14, 2009·Pediatric Hematology and Oncology·Nadia DakkaAbdelaziz Benjouad
Dec 7, 2013·Expert Review of Molecular Diagnostics·Janghee WooVivian Arguello
Sep 19, 2009·Expert Review of Anticancer Therapy·Javier Briones
Sep 18, 2009·Pediatric Blood & Cancer·Ester MejstríkováOndrej Hrusák
Apr 5, 2016·Hematology/oncology Clinics of North America·Leslie LehmannRonald D Barr
Nov 30, 2010·Best Practice & Research. Clinical Haematology·Elaine Coustan-Smith, Dario Campana
Oct 15, 2009·Hematology/oncology Clinics of North America·Dario Campana
Sep 26, 2009·Clinical Lymphoma & Myeloma·Deepa BhojwaniChing-Hon Pui
Dec 23, 2008·Seminars in Hematology·Dario Campana
Sep 19, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Stewart J Kellie, Scott C Howard
Mar 25, 2008·Lancet·Ching-Hon PuiA Thomas Look
Aug 20, 2008·British Journal of Haematology·Dario Campana
Jun 13, 2013·Cytometry. Part B, Clinical Cytometry·Giuseppe GaipaDario Campana
Apr 5, 2011·Pediatric Blood & Cancer·Neelam Varma, Shano Naseem
Aug 21, 2013·Seminars in Hematology·Ching-Hon Pui, William E Evans
Jan 16, 2013·The Korean Journal of Hematology·Dario Campana, Elaine Coustan-Smith

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.